echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > 6 best-selling anti-tumor varieties can be used by children in Hengrui, Hausen, and Yangtze River...the product has exploded

    6 best-selling anti-tumor varieties can be used by children in Hengrui, Hausen, and Yangtze River...the product has exploded

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 26, the CDE official website issued a notice that six anti-tumor varieties were selected after reviewing the list of varieties, which can be directly revised to increase the indications for children and the usage and dosage of the drug.
    We are now seeking opinions from the industry and the society.
    The 6 anti-tumor varieties are: cisplatin, ifosfamide, mesna, azathioprine, asparaginase and vindesine, involving Hengrui, Qilu, Shuanglu Pharmaceutical, Baiyunshan, Yangtze River, etc.
    Giant.

    Table 1: The specific situation of the revised opinions on adding children's medication information to the second batch of marketed drug inserts

    Source: CDE official website, compiled by Mi Nei.
    com

    Source: CDE official website, compiled by Mi Nei.
    com

    Table 2: The situation of the enterprises involved in the corresponding specifications of the 6 varieties

    Source: One-click search on Mi Nei.
    com

    Source: One-click search on Mi Nei.
    com

    According to data from Meinenet, the above-mentioned 6 anti-tumor drugs are all varieties of the 2020 National Medical Insurance Catalogue, and domestic giants such as Hengrui, Qilu, Shuanglu Pharmaceutical, Baiyunshan, and Yangzijiang have layouts.

    In 2019, the sales scale of ifosfamide injection (including 0.
    5g and 1.
    0g) in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) terminals was 190 million yuan At present, the leading company in this category is Baxter, with a market share of more than 70%.
    The domestic pharmaceutical companies Hengrui and Qilu both have a market share of over 10%.

    Vindesine injection (1mg) has a terminal sales of 120 million yuan in public medical institutions in China in 2019.
    Currently, the three domestic giants Hangzhou Minsheng Pharmaceutical, Shandong Luoxin Pharmaceutical Group, and Yangzijiang Pharmaceutical Group dominate the market.

    For a long time, my country's children's medicines have faced problems such as difficult research and development, fewer varieties of medicines, and lack of proprietary dosage forms.
    It is reported that more than 90% of the medicines do not have children's dosage forms.
    In recent years, with the continuous improvement of the drug review and approval system, more and more new children's drugs that have been declared for marketing or clinical have been included in the priority review.
    The children's drug market in my country is developing in a positive manner.
    CDE adds children's medication information to the drug inserts that are already on the market, which not only expands the number of users of the product and drives the sales of drugs, but also brings more medication options to pediatric patients so that they can have medicines available.

    Source: Minet database, CDE official website

    Source: Minet database, CDE official website
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.